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Inflammatory bowel disease (IBD) is defined as pathogenesis in the intestine in a form of 
ulcerative colitis, Crohn's disease, etc. The number of IBD patients has recently increased 
rapidly majorly due to western diet and lifestyle. Because current treatment methods of 
IBD in the field are limited in targeting specific location and accompanying side effects 
such as vomiting, burping and chest pain occur. Hence, an unmet need remains in 
suggesting new perspective of drug delivery system to overcome these problems. Here, as 
an effort to develop an intestinal wall-adhesive, target specific peptide-conjugated 
hydrogel as a means of drug delivery, we synthesize mPEG-PCL (methoxy poly 
(ethylene glycol)-block-poly(ε-caprolactone)). The mPEG-PCL exhibits molecule weight 
2 
 
of 3,200-3,500 g/mol, and its sol-gel transition occurs within the molecular weight range. 
This sol-gel makes the mPEG-PCL appropriate to load and deliver the drug to the 
inflamed area. Next, its binding affinity is increased to the colon epithelium by 
conjugating flagellin-derived peptide to the mPEG-PCL, which binds to TLR5 (Toll-like 
receptor 5) of colon epithelium. When loaded to the peptide-conjugated hydrogel, dug is 
released in a controllable fashion depending on the concentration of mPEG-PCL. Also, 
the hydrogel shows the binding specificity to intestinal cells in vitro. The results indicate 
several advantages of the peptide-conjugated mPEG-PCL as a drug delivery means: First, 
the sol-gel transition of hydrogel serves as a minimally invasive means of vehicle 
injection, an on-site depot of drug, and a concentration-dependent platform for controlled 
drug release. Second, the conjugation of flagellin-derived peptide enables drug targeting 
to inflamed areas when applied to the intestine, thereby reducing the drug amount 
compared to systemic delivery means such as oral intake or intraperitoneal injection. 
Lastly, the nano-scale micelle property facilitates not only drug delivery to inflamed areas 
but also drug invasion into the intestinal wall underneath epithelium. In conclusion, 
further optimization and examination of these functional advantages would enable a 
promising potential to address the unmet need by serving as a tunable platform for 
user-friendly, disease area -specific drug delivery to the intestine. 
 
Key words: sol-gel transition, intestinal wall adhesion, inflammatory bowel disease, 
peptide conjugated hydrogel, flagellin derived peptide 
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Inflammatory bowel disease (IBD) is chronic inflammation of the gastrointestinal 
(GI) tract that may manifest as either Crohn’s disease (CD) or Ulcerative colitis (UC).1 
IBD is one relapsing and lifelong disease that affects millions of patients worldwide and 
the global IBD treatment market is expected to reach 9,500M USD (~11 trillion won) in 
2020. Patients with IBD have uncomfortable symptoms such as abdominal pain, 
persistent diarrhea, bloody stool, rectal bleeding, weight loss and fatigue.2 Although the 
exact etiology of IBD remains unclear, we have long recognized the close relationship 
between IBD and such factors as environment, genetics, and diet.3 And one of the highest 
possible causes is an immune system malfunction such as polarization of intestinal 
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immune cells toward a Th1(T helper) response.4 IBD progression is often accompanied 
by an increase in granulomas and active monocytes, which produce significant amounts 
of eicosanoids and cytokines.5 
Currently, depending on the severity of the disease, symptomatic treatment is being 
carried out, starting with anti-inflammatory drugs which include corticosteroids 
Dexamethasone and aminosalicylates6, such as mesalamine7 (Asacol HD, Delzicol, 
others), balsalazide (Colazal) and olsalazine (Dipentum)8. For those who are in the 
second stage, immunosuppressants such as azathioprine9 (Azasan, Imuran), 
mercaptopurine10 (Purinethol, Purixan) and methotrexate11 (Trexall) are used. These drugs 
work in a variety of ways to suppress the immune response that releases 
inflammation-inducing chemicals into the body. Finally, in very severe cases, surgical 
resection is performed. However, anti-inflammatory drugs and immunosuppressants are 
accompanied by many side effects which are vomiting, burping, chest pain and shortness 
of breath through mainly non-specific oral administration 12 Side effects like these are due 
to absorption of drug into non-imflamed area since target-specific treatment is incapable. 
To overcome these side effects, target-specific drug delivery is required.  
 Target-specific drug delivery13 is important to improve therapeutic efficacy and 
efficiency for the following reasons: 1) Drug administration protocols may be simplified. 
2)Toxicity is reduced by delivering a drug to its target site, thereby reducing harmful 
systemic effects. 3) Drug can be administrated in a smaller dose to produce the desire 
effect. 4) Drug can avoid hepatic first-pass metabolism. 5) Absorption of target molecules 
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such as peptides and particulates is enhanced. 6) Dose is less compared to conventional 
drug delivery system. 
For the target-specific drug delivery, we were interested in hydrogels that are widely 
used in the pharmaceutical field. Since the first report on the medical use of 
poly(2-hydroxyethyl methacrylate) hydrogels14, research on hydrogels has continued for 
the past decades. Hydrogels can be classified according to various characteristics: their 
origin (natural, synthetic, or a combination of both), their properties (mechanical or 
physical), the nature of their polymer side groups (ionic or non-ionic), the type of 
cross-link (chemical or physical), and their response to various chemical and physical 
stimuli. (Fig. 1-A) Hydrogels can contain a considerable amount of water in a 
three-dimensional network.15 As proved at successful applications in the peritoneum and 
various parts of the body, hydrogel has high biocompatibility due to its high water 
content and physicochemical similarity with the extracellular matrix16. In particular, the 
injection-type hydrogel17 is a formulation based on a minimally invasive technique that 
can be crosslinked at the same time as in vivo injection and can be simply implanted into 
the body without a separate surgical operation. With these reasons, hydrogel is selected 
for the drug delivery system. We studied pathophysiology of IBD since we tried to 
produce the drug delivery system that can be applied to the IBD patients. 
Looking at the physiological environment of IBD, the disease causes changes in the 
tissue environment in which the expression level of TLR5 (Toll-like receptor 5) of 
intestinal epithelial cells is increased. The TLR5 recognizes the bacterial locomotion 
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component flagellin for detecting whether bacteria have crossed the gut epithelia18. TLR5 
responds to a monomeric form of flagellin from β- and γ-proteobacteria that constitutes 
the whip-like flagellar filament responsible for locomotion. Flagellin binding to TLR5 
induces MyD88-dependent signaling and activates the proinflammatory transcription 
factor, NF-κB, in epithelial cells, monocytes, and dendritic cells, which results in 
activation of innate immune responses against flagellated bacteria19. A comparative 
structural analysis of the flagellin-TLR5 complexes suggests that the LRR9 loop of TLR5 
centered in interface-B plays a critical role in flagellin binding20. Among the several 
residues, flagellin R89, E114, L93, and I111 cluster together in the center of interface-B. 
We applied the binding between TLR5 and flagellin to the specific drug delivery system 
for IBD patients. 
Among several hydrogel candidates, we selected methoxy poly (ethylene 
glycol)-block-poly(ε-caprolactone) (mPEG-PCL)21 as the basic matrix. Because of the 
four reasons, 1) It exists in a solution state at room temperature (25 OC). Relatively short 
time (1-2 mins) is required for the gelation at body temperature (37 OC), which increases 
tissue adhesion 2) Because gelation proceeds by simple precipitation rather than chemical 
crosslinking, it does not change the tissue environment. 3) mPEG-PCL consists of 
hydrophilic (mPEG) and hydrophobic (PCL). These amphiphilic properties give loading 
ability of all kinds of drugs, including both hydrophobic and hydrophilic. 4) Lastly, 
mPEG-PCL is easily functionalized because of the hydroxy group end of the PCL block. 
However, there is evident limitation of specific delivery of hydrogel to the pathogen site. 
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As previously reported, TLR5 physically bonds to the flagellin of bacteria. a 
flagellin-derived peptide was attached to the hydrogel to increase the adhesion to the 
inflamed area. For more specific targeting, we try to develop injectable drug delivery 
hydrogel system. (Fig. 1 – B and C) 
Here, we proved the adhesion and drug delivery ability of the flagellin derived 
peptide conjugated hydrogel as a drug delivery system through a series of in vitro 
epithelial cell adhesive study and drug release test using modified trans-well method. 
This drug delivery platform suggests the possibility of expansion to the other diseases as 



















Figure 1. Hydrogels classification and schematic illustration of injectable hydrogel (A) 
hydrogels can be classified according to various characteristics: their origin, properities, 
their nature of polymer side groups, the type of cross-link, and their response to various 
chemical and physical stimuli. (B) A lipophilic drug is loaded into hydrogel during gelation. 
The drug integrates into the hydrophobic core. Amphiphillic copolymer and peptide 
conjugated copolymers are suspended in phosphate-buffered saline (PBS) to yield a 
nano-size micelle particle of various sizes. (C) Injectable hydrogel to the inflamed mucosa 
are presented. The inflamed mucosa is characterized by mucus depletion, accumulation of 
hydrogel, and increased permeability of the epithelial cell layer. Peptide conjugated 






II. MATERIALS AND METHODS 
1. mPEG-PCL and peptide conjugated mPEG-PCL synthesis 
Thermosensitive mPEG-PCL polymers were synthesized by one-step ring-opening 
polymerization (ROP) of caprolactone. Firstly, 7.5 g (10 mmol) of mPEG was weighed 
and prepared in three-neck round flask equipped with a stirring bar. Distilled 24.2 ml (22 
mmol) CL was then added to the flask under vacuum conditions to remove any moisture, 
and the flask was submerged in an oil bath at 130 OC. Next, mPEG and CL were reacted 
under nitrogen purging for 1.5 hours. The synthesized polymer was then dissolved in 
dichloromethane, precipitated in cold diethylether, and dired overnight under vacuum 
condition. The mPEG-PCL diblock copolymer was prepared through ring-opening 
polymerization of e-CL (42 mmol) using MPEG (2 mmol) as an initiator in the presence 
of stannous octoate[Sn(Oct)2] in diethyl ether (4 mmol), as reported previously.22-25 
peptide was coupled to the mPEG-PCL copolymer via a CDI-mediated amidation 
reaction as follows. (i) The hydroxyl group of mPEG-PCL (0.0130 mmol) was substituted 
with an imidazole leaving group via the SN2 reaction of CDI (0.0156 mmol) in dimethyl 
sulfoxide (DMSO; 10 mL) for 24 hours, forming imidazole-carbamated MP. (ii) ED 
(0.0156 mmol) was conjugated to the imidazole-carbamated mPEG-PCL through 
imidazole displacement via an SN2 reaction in DMSO (10 mL) for an additional 24 hours. 
The reactant (aminated MP) was purified using a dialysis tube (cut-off: 1~2 kDa) for 
three days. The obtained solution was lyophilized at -90 OC for 7 days and stored in a 
freezer (-20 OC) before use. (iii) peptides were conjugated to aminated mPEG-PCL in a 
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co-solvent of DMSO/distilled water (10 mL; 1:1 v/ v%) using DMT-MM as a coupling 
agent. Purification and lyophilization were carried out in the same manner as for the 
aminated mPEG-PCL preparation.26-30 
 
 
2. Material characterization 
 The structure and molar ratio of mPEG-PCL was determined using 1H-NMR (CDCl3 
with 0.03 % v/v TMS) spectroscopy (Avance III 400-MHz NMR spectrometer; Bruker 
Biospin, Billerica, MA). PCL peaks appeared at δ = 4.10 [m, –OCH2], 2.41 [m, –CH2], 
1.74 [m, –CH2], and 1.45 [m, –CH2], while mPEG peaks were observed at δ = 4.13 [s, 
=CH2], 3.28 [s, =CH2] and peak related to peptide were observed at δ = 1.70 [m, –CH2] of 
arginine. The proportions of PCL and mPEG were determined by the area ratio between 
the 1H-NMR absorption peaks of PCL and mPEG.31 The molecular weight and 
polydispersity index were determined by gel permeation chromatography (Agilent 1200 
series; Agilent Technologies, Santa Clara, CA) against polystyrene standards with a PLgel 




3. Micelle size and Material properties (Rheometer) 
The mean diameter and polydispersity (PDI) of the micelles formed in the hydrogel 
11 
 
precursor solutions were characterized using dynamic light scattering (DLS) 
(ELS-1000ZS, Otsuka Electronics Ltd., Japan). A specific concentration of solution (1 
mg/mL) was added to a cuvette (HRA-271220; Ratiolab1, Am Siebenstein, Germany) 
and measured at 25 OC for three cycles. The hydrogel formation of the solutions was 
examined at 37 OC using the tilting method with glass vials containing each solution. Sol 
to gel transition was measured using a rheometer (Bohlin Advanced Rheometer with a 





4. SEM and TEM measurements of hydrogel 
To monitor the morphological changes that occur as the system passes through the phase 
transition, samples of the 10 wt% mPEG-PCL were prepared in gel states. The hydrogel 
samples were then carefully transferred onto a metal stub and then quickly immersed in a 
liquid nitrogen bath to minimize the formation or reinforcing of the certain interaction 
between diblock copolymers, after which they were freeze-dried at –75 OC using a freeze 
dryer. Once completely dry, the diblock copolymer samples on metal stubs were coated 
with a thin layer of platinum using a plasma-sputtering apparatus (Emitech, K575, Japan) 
under an argon atmosphere. Scanning electron microscopy (SEM) (MERLIN, Zeiss, 
Oberkochen, Baden-Württemberg, Germany) measurements were carried out on the 
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platinum-coated samples.33 The morphology of prepared micelles was observed under a 
transmission electron microscope (TEM) (H-6009IV, Hitachi, Japan): micelles were 
diluted with distilled water and placed on a copper grid covered with nitrocellulose.34 The 




5. Drug release with modified trans-well method 
Dexamethasone (Dex) was loaded on the inside of the 6,8,10 wt % of mPEG-PCL 
hydrogel to induce gradual occlusion of the hydrogel. Analysis of the volume of Dex 
released35,36 by the hydrogel was performed using an Agilent Technologies 1260 Infinity 
II system (Agilent Technologies Inc., Santa Clara, CA) equipped with a degasser, a 
quaternary pump, an autosampler, and a UV detector. The samples were separated using 
an Agilent Poroshell, 120 EC-C18 4 µm, 46 x 100 mm (Agilent, part no. 695970-902 (T)), 
which was maintained at 22 OC with a detection wavelength of 242 nm. 
Acetonitrile-water 25-75 (v/v %) was used for the mobile phase at a flow rate of 1ml 
min-1, and a sample injection volume of 5µL. The peaks were identified by their retention 
times in comparison to the external Dex calibration. 5% of Tween 80 solution in Distilled 
water (DW) was used as a solvent for testing the release of Dex, and the volume of Dex 





6. Cell culture 
The IEC18 cell line was obtained from the Seoul National University Hospital Cell Line 
Bank (Seoul, Republic of Korea). Cells were treated with 4mM Butyrate or vehicle for 24 
h for gamma count analysis and flow cytometry. Cytochalasin B (2.5 μM, Sigma-Aldrich), 
a GLUT inhibitor, or phlorizin (100 μM, Sigma-Aldrich), an SGLT inhibitor, was 
administered 30 min before incubation with FDG.  
 
 
7. Cytotoxicity of mPEG-PCL Micelles 
The cytotoxicity of mPEG-PCL micelle was evaluated by cell viability assay on L929 
cell line and IEC-18 cell line. Briefly, L929 and IEC-18 cells were plated at a density of 
5×103 cells per well in 100 μL DMEM medium in 96-well plates and grown for 24 h. The 
cells were then exposed to a series of mPEG-PCL micelles at different concentrations for 
48 h, and the viability of cells was measured using the CCK-8 method. 
 
 
8. PCR and qPCR  
Total RNA was extracted from cells and tissues by Trizol (Invitrogen) following the 
manufacturer’s instructions and quantified using a NanoDrop™ 2000 Spectrophotometer 
(Thermo Fisher Scientific). Complementary DNA (cDNA) was produced by 
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AccuPower® CycleScript RT Premix (Bioneer) according to the manufacturer’s 
instructions using the T-100 Thermal Cycler (Bio-Rad) and subjected to PCR on the T100 
Thermal Cycler (Bio-Rad) with a primer set and a HiPi Plus 5×PCR premix (Elpisbio), 
followed by agarose gel electrophoresis. qPCR was carried out using cDNA, primer set, 
and SYBR Green PCR mix (Applied Biosystem) on StepOne Plus Real Time PCR 
System (Applied Biosystems), followed by melting curve analysis. Each result was 
normalized to the corresponding amount of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) or ribosomal protein S18 (RPS18). The values were analyzed by the 
comparative Ct (2-∆∆Ct) method, and further normalized to that of negative control. The 
primer sequences used in the reaction are listed in Table 1. Microarray was performed to 
profile the microRNA content of the TMNV using GeneChip 4.0 microRNA Microarray 
(Affymetrix, Japan) according to the manufacturer’s instructions. 
 
 
9. Western blotting 
Total proteins were extracted by lysing samples with RIPA buffer (Sigma-Aldrich), 
followed by amount quantification using Bradford assay (Sigma-Aldrich). Protein 
extracts were run on a 10% (w/v) SDS–polyacrylamide gel (SDS–PAGE gel) and 
electro-transferred onto a nitrocellulose membrane, followed by blocking in TBST (20 
mM Tris, 0.9% NaCl, 0.1% Tween 20, pH 7.4) with 5% (w/v) skin milk for 1h at RT. 
Membranes were incubated with primary rabbit anti-CD31 (PECAM1) (1/200, Abcam), 
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rabbit anti-caspase3(1/1000, Abcam), rabbit anti-Ki67(1/1000, Abcam), rabbit 
anti-Notch1(1/1000, Abcam) and mouse anti-β-actin(1/1000, Abcam) antibodies diluted 
in 5% skin milk, followed by treatment of secondary goat anti-Rabbit IgG (H+L)-HRP 
conjugated (1/5000, Abcam) antibodies. The signals were visualized using the Clarity 
Western ECL Substrate (BIORAD, Republic of Korea) according to the manufacturer’s 
instruction, and analyzed using LAS-3000 (Fujifilm, Japan). 
 
 
10. Immunofluorescence staining 
Immunofluorescence staining was performed by recycling the cell plate by removing the 
antigen via heating with citrate buffer treatment (C9999, Sigma-Aldrich, St. Louis, MO, 
USA). The plate were permeabilized with 0.3 % Triton X-100 (93443, Sigma-Aldrich, St. 
Louis, MO, USA) in PBS for 15 min and blocked with 5 % BSA for 1 hours. The sample 
plate were then incubated with primary mouse anti-TLR5 (1:100 dilution; ab24590, 
Abcam, Cambridge, Cambridgeshire, UK), washed with PBS containing 0.5 % Tween 20, 
and reacted with secondary anti-rabbit conjugated to Alexa Fluor 594 (1:200 dilution; 
115-545-144, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) The cell 
nuclei were counter-stained with NucBlueTM Live ReadyProbesTM Reagents (7817, 
Invitrogen, Waltham, MA). Finally, the plates were subjected to optical or confocal 
imaging (LSM700, Zeiss, Oberkochen, Land Baden-Württemberg, Germany), followed 
by image analysis using ImageJ/Fifi software (NIH).  
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11. Statistical analysis 
All the results were presented as mean ± standard deviations (SD). Statistical analysis 
was conducted using a t-test for more than two groups with one factor or two-way 
ANOVA with Bonferroni’s and Tukey’s post hoc analysis for more than two groups with 



















Table 1. PCR primer list 
 Accession number Primer sequence (5’-3’)  
TLR5 NM_002467.5 F- AAA AGC AGC AGT ATT TGA GG 
R- ACT AGG AAA CCG TCC TTA TG 
GAPDH NM_004235.5 F- CTC ATG ACC ACA GTC CAT GC 
R- TTC AGC TCT GGG ATG ACC TT 
beta-Actin NM_006500.2 F- AGC CAT GTA CGT AGC CAT CC 
R- CTC TCA GCT GTG GTG GTG AA 
NF-kB NM_002507.3 F- TAC CCT CAG AGG CCA GAA GA 
R- TCC TCT CTG TTT CGG TTG CT 
MyoD88 NM_022551.2 F- GCT GAC TTG GAG CCT GAT TC 
R- GAT AGG CAT GTC AGG GGA GA 
IL6 NM_001135.3 F- CCG GAG AGG AGA CTT CAC AG 
R- ACA GTG CAT CAT CGC TGT TC 
IL-8(h) NM_000346.4 F- ATG ACT TCC AAG CTG GCC GTG 




1. Synthesis and characterization of mPEG-PCL copolymer. 
mPEG-PCL(MP) di-block copolymers synthesize was illustrated in (Fig. 2-A) by 
one-step ring-opening polymerization (ROP) of caprolactone. The synthesis method is 
comparable to previously developed PLGA-g-PEG37, with the difference being that the 
monomers of lactide and glycolide were replaced by caprolactone. The molecular weight 
is a critical factor of MP sol-gel transition. The molecular weight of synthesized MP is 
affected by the amount of catalyst, temperature, reaction time, and the ratio of mPEG and 
PCL. We performed the experiment by adjusting the ratio of mPEG : PCL while other 
factors are fixed. We proceeded with the synthesis by gradually increasing the ratio of CL 
starting with the 1 : 5 ratio of mPEG : PCL. In the case of mPEG : PCL at a molar ratio of 
1 : 5, the yield was low. At a ratio of 1 : 10, We obtained a molecular weight of 3,027 
g/mol, slightly lower than the target molecular weight which is 3,200-3,500 g/mol. 
Finally, when the ratio of mPEG : PCL became 1 : 12.5. the target molecular weight range 
of 3,461 g/mol was obtained. When the ratio was increased to 1:25, the molecular weight 
of 8.539 g/mol waws obtained. (Fig. 2-B) With this results, nearly linear curve 
(R2=0.9987) representing the molecular weight depending on ratio of CL to Sn(Oct)2 was 







Figure 2. Synthesis and characterization of MP di-block copolymer. (A) MP polymers 
synthesize was illustrated by one-step ring-opening polymerization (ROP) of 
caprolactone (B) The synthesis conditions and results of MP di-block copolymers are 












2. Candidate peptides screening and selection with computational binding 
affinity. 
In order to increase the accuracy delivery of hydrogel to the inflamed region, a peptide 
that can physically adhere to the TLR5 expressed intestinal epithelial cells was screened 
using previously reported study and glide program. One receptor (TLR5) in the dataset is 
docked with 7 peptides contained in the dataset. (Fig. 3-A) Then, the 7 target peptides 
were ranked based on the docking score. (Fig. 3-B) Two peptide ,Candidate 
2(QRMRELTV) and 3(QRMRELRVQ), were selected according to the docking score 
close to -10.38 And also, candidate1(QRE), which includes only hot spot of flagellin 
amino acid, Glutamine (Gln), Arginine (Arg) and Glutamate (Glu), found in the previous 
study, was selected. (Fig. 3-C)39 To evaluate actual adhesion to the TLR5 in vitro, 
fluorescamine and alpha imager assay40 was employed. To confirm the adhesion of the 
three candidate peptide groups, the test was performed to the IEC-18 (Intestinal epithelial 
cells-18) with or without TLR5 overexpression. Candidate 1(QRE) showed the lowest 
IEC-18 adhesion in the TLR5 overexpressed group. On the other hand, Candidate 
2(QRMRELTV) and Candidate3(QRMRELRVQ) showed high adhesion in the TLR5 
overexpressed group. Compared to Candidate 1(QRE), Candidate 2 (QRMRELTV) showed 
increase of 43 ± 3.5 % in adhesion, and Candidate 3(QRMRELRVQ) showed an increase 
of 21 ± 4.12 %. Among the peptide candidates , the highest adhesion (Fig. 3-D) was 
observed in the Candidate 2 composed of 8 amino acids (QRMRELTV).41 This correlated 




Figure 3. Binding interface and ranking the scores of flagellin derived peptide 
candidates. (A-B) Illustration of the multiple grid arrangement method. Red dots on the 
protein indicate a predicted peptide binding site, and blue dots show receptor grids for 
peptide docking. The multiple grid arrangement method can cover an entire space of any 
predicted ligand-binding site automatically. (C) The complex models were arranged 
according to their scores, and rankings were assigned. Selected peptide candidates are 
listed in the table. (D) In vitro adhesion test of peptide candidates to the IEC-18 (Intestinal 
epithelial cells-18) with or without TLR5 overexpression. All data are shown as the mean 




3. Preparation and 1H NMR characterization of peptide conjugated MP 
A scheme for conjugation of peptides to the MP backbone is shown. (Fig. 4-A) 
Conjugation of peptide to MP was confirmed with 1H NMR analysis using a solvent of 
chloroform-d6. 31 The signals at 3.53 and 3.68 ppm were assigned to the methyl and 
methylene groups of mPEG, respectively. The peaks (yellow circle) at 4.21–4.39, 3.73, 
2.09–2.12, and 1.88–1.97 ppm were attributed to PCL. Three peaks related to peptide (red 
circle) were observed at 3.40 ppm for the aspartic acid, at 4.08 ppm for the of glycine, and 
at 1.70 ppm for the arginine. The relative intensities of the signals at 3.53 and 3.40 ppm, 
which were assigned to the methyl group of mPEG (brown circle). (Fig. 4-B) To quantify 
the actual amount of peptide in the peptide conjugated polymers, Sakaguchi assay which 
detects the guanidine group in the arginine of peptide the was employed.40 MP-Peptide 1.0, 
2.0, 3.0, 4.0 represents how much peptide should be theoretically conjugated when 1.0, 2.0, 3.0, 
4.0 mM of peptide are reacted with MP. The UV–Vis spectra of the MP and MP-peptide 
samples treated with Sakaguchi reagents. The MP-peptide samples exhibited maximum 
absorption around 520 nm and we could observe normalized absorbance of approximately 
0.1, 0.17, 0.25, 0.31 from MP-Peptide 1.0, 2.0, 3.0, 4.0 respectively. (Fig. 4-C) With this 
normalized absorbance, the peptide concentration calculated using the standard curve of 
acetylated glycine which content is fixed. (Fig. 4-D) In the case of MP-peptide4.0, 3.1 ± 
0.22mM of peptide was attached to the MP implying that approximately 70% of the 
peptide was stably attached to the MP. In the case of MP-peptide1.0, 2.0,3.0, 0.8 ± 0.41mM, 1.6 
± 0.4mM, 2.7 ± 0.11mM of peptide was respectively attached to the MP with conjugation 
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percentage of 70- 75%. From the results above, we confirmed that the peptide conjugated 













Figure 4. Schematic illustration and 1H NMR spectra of peptide-conjugated MP. (A) 
The hydroxyl group at the one side of mPEG-PCL was aminated with ED via the imidazole 
displacement of SN2 reaction using CDI, followed by conjugation of peptide via 
condensation reaction using DMT-MM as a condensing agent. CDI- 
N,N-carbonyldiimidazole; ED-ethylenediamine. (B) 1H NMR spectra of peptide conjugated 
hydrogel measured in a solvent of chloroform-d6. (C-D) Sakaguchi assay was analyzed for 






4. Rheological properties of hydrogel. 
 
We demonstrated the sol-gel transition by precipitation of MP-peptide mixed copolymer. 
The copolymer exists as a solution at room temperature (25 OC) and becomes a gel around 
the body temperature (37 OC) which means its suitability as a drug delivery system. (Fig. 
5-A) The viscoelasticity of 5, 10 (w/v) % hydrogel was measured through a frequency 
sweep of a rheometer, a powerful theology tools for the study of fluid and soft body 
systems. (Fig. 5-B)  
Compared to the sol state, the storage modulus(G’) in the gel state showed a larger increase 
than the loss modulus(G”). In the body temperature range (=37 OC), the storage modulus 
(G’) was greater than the loss modulus (G”) in both 5 (w/v) % and 10 (w/v) % hydrogel. It 
implies that the hydrogel exists as gel state at body temperature. The elastic modulus and 
elasticity of the hydrogel were calculated by the storage(G’) and loss modulus(G”) of 
hydrogels (5,10 (w/v) %) measured through frequency sweep. A stiffer material, 10 
(w/v) % hydrogel in (Fig. 5-C), will be characterized by a 4 times higher elastic modulus 
than that of 5 (w/v) % hydrogel. High elastic modulus and low elasticity indicate high 
strength of the material. To understand the sol-gel transition process of 5 (w/v) % MP 
hydrogel, temperature sweep measurements were performed. More specifically, the storage 
modulus (G’) represented the elastic behavior and the loss modulus (G”) denoted the 
viscous behavior were monitored as a function with temperature.35 As illustrated in (Fig. 
5-D), it was clearly observed that the loss modulus(G”) was greater than storage modulus 
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(G’) as temperature was lower than 32 OC, corresponding to the sol state of system. As 
gelation proceeds, the storage modulus(G’) was equal to loss modulus(G”) at 32 OC, 
indicating the sol–gel transition temperature of system. Subsequently, storage(G’) and 










Figure 5. Sol–gel transition behavior of mPEG-PCL mechanical properties of hydrogel 
(A) Thermosensitive MP micelles are prepared through self-assembly of amphiphilic 
di-block copolymers. (B-C) Rheological properties was detected using rheometer. (D) 
hydrogel sol-gel transition was observed with temperature sweep measurements. All data 






5. Size distribution of spherical micelles and in vitro drug release. 
 
The morphology and size distribution of the MP hydrogel was measured by 
scanning electron microscopy (SEM), transmission electron microscope (TEM) and 
dynamic 
light scatting (DLS). To evaluate the structure of MP in aqueous solution, we prepared a 
sample by lyophilizing 5 (w/v) % MP hydrogel. The highly interconnected porous 
morphologies with macropores larger than 10 µm and irregular shapes are observed. To 
observe micelle structure in MP hydrogel, we prepared a sample by lyophilizing low 
concentration (= 10-2 (w/v) %) MP hydrogel. (Fig. 6-A and B) The particle size of MP 
micelles at the low concentration of MP hydrogel measured by DLS was 105 ± 5.38 nm 
(PDI = 0.228). (Fig. 6-C) Nano size micelles means, these structures penetrate in the tissue 
system, facilitate easy uptake of the drug by cells, permit an efficient drug delivery and 








Figure 6. Structure of MP in aqueous solution and size distribution of spherical 
micelles. (A) The morphology of MP was observed under a SEM. And nano size micelle 
structure was observed under a SEM and TEM at the low concentration ( <10-2) of MP 
hydrogel. (C) MP basically formed spherical micelle structure in an aqueous environment 
and mean diameter (=105± 5.38 nm) of the spherical micelles was detected by DLS particle 






6. In vitro disease modeling and evaluation 
 
The cytotoxicity of MP, peptide, MP-peptide on the L929, IEC-18 cells were evaluated 
using the Cell Counting Kit-8 (CCK-8) assay (Promega, Madison, WI) according to the 
manufacturer’s instructions. As shows in (Fig. 7-A), The cell only treated with DMEM 
media was selected as control group, treated with MP kept a viability of 93.3%. Cells 
treated with peptide still kept a viability of 95.6% even at a high concentration of 20µM 
peptide and MP-peptide (peptide conjugated MP) kept a viability of 92.4%. We can 
observe no significant cell cytotoxicity in every group.  
In order to make in vitro disease model, we treat butyrate to the IEC-18. Butyrate 
induced TLR5 mRNA expression in a dose- and time-dependent manner with the highest 
levels (approximately 4 times higher than control group) of expression noted after 
treatment with 4 mM of butyrate for 24 hours42 (Fig. 7-B).  
With TLR-5 overexpressed epithelial cells, we treated 100ng/ml flagellin as positive 
control and 20µM candidate peptides to observe cascade signaling of NF-kB, IL-6 and TNF- 
α mRNA expression with qRT-PCR.43 (Fig. 7-C) The cell signaling means that it is caused 
by the binding of the peptide and TLR5 receptor on the epithelial cell surfaces which means 
peptide candidate are well attached to TLR5. Compared with control group, in the group 
treated with flagellin, NF-kB, IL-6, TNF- α expression level of was increased by 32.7 ± 4.72, 
58.5 ± 5.12, 47.2 ± 2.98, respectably. Also, among peptide candidate, the peptide composed 
of 8 amino acid (QRMRELTV) NF-kB, IL-6, TNF- α expression level of mRNA was 
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increased by 10.2 ± 1.72, 8.75 ± 3.52, 13.8 ± 3.98, respectably. Peptide composed of 8 
amino acid slightly similar cell signaling of flagellin treated group. With this result, we 
confirm that the peptide composed of 8 amino acid has the best TLR5 adhesion ability.  This 












Figure 7. Cell signaling by binding of flagellin derived peptide and TLR5 receptor. (A) 
Biocompatibility was observed in L929 and IEC-18 cells. (B) qRT-PCR showing TLR5 
mRNA expression in IEC-18 cells treated with physiological concentration of butyrate 
(4mM) for 24h. (C) qRT-PCR showing IL-6, TNF- α mRNA expression in TLR5 
overexpressed IEC-18 cells treated with 100ng/ml flagellin and 20µM peptides (D-E) 
Compared with control group, the expression of nuclear protein of NF-ĸB, total protein of 
IL-6 significantly increased in flagellin (Positive control) group and slightly increased in 
peptide composed of 8 a.a(QRMRELTV) group. Abbreviations: a.a , amino acid. All data 





7. In vitro peptide conjugated MP adhesion of TLR5 
 
Backbone hydrogel and MP hydrogel adhesion to the IEC-18 surfaces was confirmed in 
comparison with or without TLR5 overexpression. Following the pre-defined washing, the 
remaining peptide conjugated MP hydrogel (MP-peptide hydrogel) (red fluorescent labeled) 
was located between the cells, also found at cell membrane surface. In particular, the 
hydrogel adhesion was clearly increased to TLR5 overexpressed IEC-18.  Indicating that 
conjugation of flagellin-derived peptide successfully promoted target specific hydrogel 
adhesion. (Fig. 8-A) This result was also confirmed by the quantitative results from image 
analysis of the mean intensity of hydrogel per cells. Compared normal IEC-18, 0.04 ± 
0.005 of adhesive MP-peptide hydrogel intensity was confirmed from in the TLR5 
overexpressed IEC-18, which was significantly higher than that in normal IEC-18 (0.02 ± 












Figure 8. Peptide conjugated hydrogel attachment of TLR5 overexpressed epithelial 
cells.  (A-C) Immunocytochemical identification of TLR5 overexpressed IEC-18 and 
MP-peptide hydrogel adhesion. MP-peptide was identified by alexa 594TM NHS Ester 
Subbinimidyl Ester (red) IEC-18 by alexa 488TM(green) immunostainign. The nuclei of all 
cells were idenrifed by DAPI(blue). All data are shown as the mean ± S.D. *p < 0.05, **p 








8. In vitro drug release test of MP-peptide with various concentration 
 
Among various IBD drugs, we used Dex as a model drug. In vitro release behaviors of 
Dexamethasone (Dex) from MP-peptide hydrogel was investigated using a modified 
transwell drug release method. In comparison with MP-peptide hydrogel, 10 w/v % 
MP-peptide hydrogel showed a much slower cumulative release behavior. As shown in 
(Fig. 9-A), 23 ± 4.04% of Dex was released from MP-peptide hydrogel in the first 12 
hours, which was significantly lower than that in 6, 8 w/v% of MP-peptide hydrogel 
group (37 ± 6.22% and 32 ± 4.72% respectively. P <0.01). 35,36,44 In the 48 hours, 60.6 ± 
5.28% of Dex was released from MP-peptide hydrogel, which was significantly lower 
than that in 6, 8 w/v% of MP-peptide hydrogel group (98.7 ± 1.1% and 78.0± 3.62% 
respectively. P <0.001). Control of drug release depending on the concentration of 












Figure 9. Drug release from various concentration of MP hydrogel. (A) Schematic 
illustration of modified transwell drug release test. (B) Release behavior of Dex from Dex 
loaded MP hydrogel was observed using HPLC. All data are shown as the mean ± S.D. *p 















 Inflammatory bowel disease(IBD) is a disease that cause chronic inflammation of the 
gastro-intestinal tract, and has principal forms of Crohn’s disease and ulcerative colitis. The 
therapeutic approach to patients with IBD includes three aspects, pharmacological therapy, 
nutritional support, and surgical intervention. Local and systemic administration of 
mesalazine is used in early stages, systemic corticosteroids, immune suppressive agents such 
as azathioprine, 6-mercaptopurine, TNA-α inhibitor are advised.  
Because IBD medication such as corticosteroid, immunosuppressive agent might cause 
adverse side effect including an increased susceptibility to infection, medical therapy for 
IBD need a balance of intended therapeutic effects and unwanted adverse side effects. For 
achieving and/or optimizing the desired therapeutic effect and minimizing adverse effects, 
various drug delivery approaches that developed in decades. Because pharmacokinetic 
and pharmacodynamic properties of oral formulations for IBD patient drug delivery rely 
on pH-, time-, microflora-, or pressure-triggered mechanisms, novel disease-targeted drug 
delivery strategy development is an important challenge.  
MP-peptide hydrogel as a drug delivery system use specific features of the inflamed 
region. Here, we demonstrate that MP-peptide hydrogel preferentially adhere to TLR5 
expressed epithelial cell surfaces. Additionally, flagellin plays a role of pathogen in IBD 
pathophysiology, result in increasing level of NF-kB, IL-6, TNF-α expression level. In that 
peptide candidate attached to TLR5 and slightly increase the expression level of NF-kB, 
IL-6, and TNF-α, MP-peptide hydrogel may has a antagnostic effect to hydrogel. 
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The structure of MP-peptide hydrogel in aqueous solution, highly interconnected 
porous morphologies and irregular shapes are observed. However, in the low 
concentration of MP-peptide hydrogel in aqueous solution, the nano-size of the micelle 
are observed. These micelle structure means interconnected gel like porous morphologies 
consist of micelles interaction by precipitation. The nano size micelle structures of 
MP-peptide represent possibility of drug delivered directly to the inflamed intestine and 
then gradually drug release. 
Potential applications are not limited to IBD but include any disease where controlled 
drug release at a distinct location is desired. Through attaching to the inflamed mucosa 
and selectively releasing drug at the site of inflammation, this system has the potential to 
prolong local drug availability, minimize systemic drug absorption, reduce dosing 
frequency, and lower the burden on the patient, all of which should improve compliance, 
reduce the risk for systemic toxicity, and maximize therapeutic efficacy.  
This study suggests that MP-peptide hydrogel generate a reservoir of drug at the site 
of inflammation, thereby gradually release of local drug availability. Drug delivery using 
MP-peptide hydrogel direct injection to the target region may thus allow for less frequent 
dosing in patients with IBD. Compared with other drug delivery systems targeting the 
inflamed colon, peptide conjugated hydrogel has several potential advantages. First, the 
MP-peptide hydrogel described here is made from a nontoxic, FDA approval compound, 
which should facilitate rapid translation into the clinic. Second, the characteristic of being 
sol at room temperature and sol at body temperature is suitable for target drug delivery. 
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Third, a functionalized peptide to the hydrogel increase the adhesion of the inflamed area. 
























In summary, this study offers a novel solution to a long-standing issue in specific target 
drug delivery by demonstrating the potent theragnostic function of peptide conjugated 
hydrogel. This theragnostic effect can be exerted by the synergistic function of corticoid 
steroid drug such as dexamethasone. Moreover, MP-peptide hydrogel was validated not 
only in the adhesion effect in vitro experiments but also released amount of drug is 
controllable depending on the concentration of MP-peptide hydrogel. And most 
importantly, target specific drug delivery, reducing the cost and burden to patients. These 
promising results suggest that peptide conjugated hydrogel is a potential drug delivery 
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염증성 장 질환 치료 연구를 위한 소장벽 점착성 하이드로겔 개발 
 
<지도교수 성 학 준> 
 
연세대학교 대학원 의과학과 
 
김 태 영 
 
염증성 장 질환(IBD)는 크론병과 궤양성대장염의 한 형태로 장내 염증성 
병인으로 정의된다. 근대화, 서양식 식단 등의 원인으로 인해 IBD 환자 수가 
급격히 증가하고 있으며 대증적 치료수단을 이용한 증상완화에 초점을 맞추고 
있다. 현재 IBD 치료약인 항염증제와 면역억제제는 구강 섭취로 소장과 
대장에 전달된다. 위 약물은 설사, 혈변, 면역력 감소등의 부작용을 
동반하는데 이는 염증 부위로의 표적 약물 전달이 불가능하기 때문이다. 이를 
극복하기 위해 효율적인 장벽 특이적 약물전달 치료수단이 필요하다. 여기서, 
우리는 mPEG-PCL를 기본 모체로 장벽 염증부위 특이적 약물 전달 
하이드로겔을 개발하였다. 약물전달체의 장벽부착능력을 증가시키기 위해 
편모 유래 펩타이드를 하이드로겔에 부착하였다. 편모는 장외벽에 발현하는 
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TLR5와 상호작용을 하는 펩타이드이다. 우리가 개발한 약물전달체는 
상온에서 졸 상태로 존재하다 체온에서 젤상태가 된다. 이러한 졸 젤 전이는 
약물을 담지하고 염증부위에 전달하는데 유용하다. 또한, 약물전달체의 농도를 
조절함에 따라 약물의 방출 속도 조절이 가능하다. 표적 특이적 약물전달체의 
개발은 몇 가지 이점을 지닌다. 첫째, 표적 특정 약물 전달을 통해 염증 
부위에만 약물을 전달할 수 있다. 따라서, 필요한 약물의 양은 경구 투여로 
인해 섭취하는 양에 비해 현저히 감소한다. 둘째, 약물을 지속적으로 방출하며, 
약물의 효과가 더 오래 지속된다. 마지막으로, 염증부위로의 특이적 약물 
전달은 다른 질병에 사용함에 있어 확장성이 있다. 결론적으로, 장 외벽 접착, 
표적 특이적 약물전달 시스템으로 인해 사용해야하는 약물의 양을 줄이고 
표적 특이전달 및 지속방출을 증가시켜 약물의 부작용을 줄일 수 있다. 
핵심되는 말 : 장 외벽 접착성, 염증성 장 질환, 펩타이드 결함 하이드
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